Evaluation 1 of "Pharmaceutical Pricing and R&D as a Global Public Good"

Evaluator 1

No 2025-29, The Unjournal Evaluations from The Unjournal

Abstract: This paper provides a comprehensive analysis of pharmaceutical research and development (R&D) as a global public good, highlighting the contributions made by various countries. It successfully gathers valuable data and employs innovative methods to calculate marginal costs. However, the empirical approach could be improved by addressing omitted variable bias and incorporating general equilibrium effects.

Date: 2025-06-15
References: Add references at CitEc
Citations:

Published in The Unjournal

Downloads: (external link)
https://unjournal.pubpub.org/pub/e1pharmpricing (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:bjn:evalua:e1pharmpricing

DOI: 10.21428/d28e8e57.072621d7/97c1c625

Access Statistics for this paper

More papers in The Unjournal Evaluations from The Unjournal
Bibliographic data for series maintained by Davit Jintcharadze ().